ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 53

Adenosine A2A Receptor As a Potential New Therapeutic Target For The Prevention/Treatment Of Osteoarthritis

Aranzazu Mediero1, Tuere Wilder2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, 3Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, osteoarthritis and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis, the most common type of arthritis in the United States, results from trauma and other mechanical factors as well as metabolic changes in bone and cartilage.  We have previously demonstrated that adenosine, acting via the A2A receptor, inhibits inflammation and plays a critical role in regulating bone metabolism. Thus, adenosine A2A receptor knockout mice are osteopenic as a result of increased osteoclast number and activity. We have observed that aging adenosine A2A receptor knockout mice experience difficulty in movement, taking food and walking and so we determined whether changes in their bone or joint structure or function could explain these changes.

Methods: 4 month old C57Bl/6 wild type (WT) and A2AKO mice (n=4) were sacrificed and knee joints were prepared for microCT analysis and histology. PAS (Periodic Acid Staining) and Trichrome staining of decalcified sections of leg were carried out. MicroCT analysis of knees of WT and KO mice were carried out and analysis of bone was performed on the distal femur below the growth plate.

Results: microCT analysis of the knees of A2AKO mice showed osteophyte formation together with mild remodeling and subchondral sclerosis when compared to WT mice. As we have previously reported A2A KO mice suffered from osteopenia; bone volume/total volume (BV/TV) was significantly decreased in A2AKO mice when compared to control (33.324±0.56 vs 35.782±0.78, respectively, p<0.01). The same decrease was observed for trabecular thickness (0.0685±0.0035 vs 0.081±0.002, p<0.05) and bone mineral density (BMD) (0.3795±0.003 vs 0.4265±0.01, respectively, p<0.5), with no change in trabecular number (4.8795±0.17 vs 4.646±0.23, p=ns). H&E and trichrome staining showed a loss in collagen in the cartilage together with diminished subchondral bone and chondrocyte hypertrophy and proliferation. PAS staining correlated with these results showing a loss in proteoglycans both in the articular cartilage and in the growth plate in A2AKO mice together with an increase in chondrocyte proliferation.

Conclusion: Deficiency in adenosine A2A receptors leads to spontaneous osteoarthritis and suggests that adenosine receptors may be novel targets for development of therapies to ameliorate or prevent osteoarthitis.


Disclosure:

A. Mediero,

Filed a patent on use of adenosine A2AR agonists to prevent prosthesis loosening (pending). ,

9;

T. Wilder,
None;

B. N. Cronstein,

Canfite Pharma,

1,

NIH, Gilead, Takeda, AstraZeneca,

2,

NYU School of Medicine,

3,

Merck-SeronoBristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector,

5,

Multiple patents on adenosine receptors and bone metabolism, pharmacology,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-as-a-potential-new-therapeutic-target-for-the-preventiontreatment-of-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology